Payment overview · 2025
General Payments
$112.59
7 reported records · 4 companies
Healthcare provider profile · identity verified
Jace A Bird, DO
Allopathic & Osteopathic Physicians|Family Medicine · FORT BENTON, MT · NPI 1477627982
Verified facts
What the public records show
CMS Open Payments records show Jace A Bird, DO received $112.59 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 44.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.60 | 44.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.99 | 25.8% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.87 | 16.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.13 | 12.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $112.59 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.78 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.99 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.99 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| BEVESPI AEROSPHERE Normalized: bevespi aerosphere |
Drug | AstraZeneca Pharmaceuticals LP | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 116 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 453 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 428 | 49 |
| Lisinopril | Lisinopril | 311 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 276 | 46 |
| Metformin Hcl | Metformin Hcl | 263 | 37 |
| Losartan Potassium | Losartan Potassium | 248 | 42 |
| Simvastatin | Simvastatin | 237 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 210 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 210 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 33 |
| Furosemide | Furosemide | 195 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 29 |
| Gabapentin | Gabapentin | 175 | 26 |
| Allopurinol | Allopurinol | 169 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 24 |
| Omeprazole | Omeprazole | 141 | 25 |
| Potassium Chloride | Potassium Chloride | 139 | 25 |
| Sertraline Hcl | Sertraline Hcl | 136 | 17 |
| Celecoxib | Celecoxib | 132 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 19 |
| Eliquis | Apixaban | 116 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 22 |
| Tramadol Hcl | Tramadol Hcl | 101 | 32 |
| Donepezil Hcl | Donepezil Hcl | 89 | suppressed |
| Ezetimibe | Ezetimibe | 88 | suppressed |
| Spironolactone | Spironolactone | 87 | 14 |
| Bumetanide | Bumetanide | 69 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 14 |
| Propranolol Hcl | Propranolol Hcl | 69 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 22 |
| Trazodone Hcl | Trazodone Hcl | 66 | 13 |
| Baclofen | Baclofen | 64 | suppressed |
| Meloxicam | Meloxicam | 64 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 56 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 55 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 54 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 54 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 54 | 11 |
| Fentanyl | Fentanyl | 53 | suppressed |
| Myrbetriq | Mirabegron | 52 | suppressed |
| Famotidine | Famotidine | 50 | suppressed |
| Olanzapine | Olanzapine | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 13 |
| Prednisone | Prednisone | 45 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 19 |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Calcitriol | Calcitriol | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Austedo | Deutetrabenazine | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 14 |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Topiramate | Topiramate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $112.59 · 7 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BEVESPI AEROSPHERE, ELIQUIS, Korlym, MOUNJARO, NURTEC ODT, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error